FY2025 · ended Dec 31, 2025 · Revenue $3.44B, +2.1% YoY · Filed Feb 27, 2026
Bruker Corporation (BRKR) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.4 billion and a net loss of $8.6 million. Free cash flow was $43.3 million. As of Sep 30, 2026 it held $119.7 million in cash and investments and $1.7 billion in total debt.
Revenue (TTM)
$3.51B
+2.2% vs year-ago TTM
Net income (TTM)
$-123.40M
-490.4% vs year-ago TTM
Operating cash flow (TTM)
$341.80M
+262.5% vs year-ago TTM
Free cash flow (TTM)
$244.70M
+2408.5% vs year-ago TTM
EPS (TTM)
$-1.10
-603.6% vs year-ago TTM
Dividend per share
$0.20
+0.0% vs prior year
Shares outstanding
152.14M
+0.3% vs prior year
Net cash
$-1.59B
as of Sep 30, 2026
Operating margin
-2.0%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BRKR (Nasdaq), BRKRP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Billerica, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1109354
- Former names
- BRUKER BIOSCIENCES CORP (until Feb 27, 2008); BRUKER DALTONICS INC (until Jul 2, 2003)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- 10x Genomics, Inc. TXG
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.4B | $3.4B | $3.0B | $2.5B | $2.4B |
| Operating income | $68.2M | $253.1M | $436.9M | $432.7M | $413.3M |
| Net income | -$8.6M | $113.1M | $427.2M | $296.6M | $277.1M |
| Diluted EPS | -$0.15 | $0.76 | $2.90 | $1.99 | $1.81 |
| Operating cash flow | $134.1M | $251.3M | $350.1M | $274.4M | $282.4M |
| Free cash flow | $43.3M | $136.0M | $243.2M | $145.2M | $190.4M |
| Total assets | $6.2B | $5.8B | $4.2B | $3.6B | $3.6B |
| Total liabilities | $3.7B | $4.0B | $2.8B | — | — |
| Stockholders' equity | $2.5B | $1.8B | $1.4B | $1.1B | $1.1B |
| Cash and investments | $298.8M | $183.4M | $488.3M | $645.5M | $1.2B |
| Total debt | $2.1B | $2.3B | $1.4B | $1.3B | $1.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 1004 Bruker Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.